All News

Stop,pills,water

ICYMI: Can Mycophenolate be Stopped in Stable SLE?

Jack Cush, MD

In patients with clinically stable systemic lupus erythematosus (SLE) and lupus nephritis, the withdrawal of mycophenolate mofetil was not significantly inferior to mycophenolate maintenance, but MMF withdrawal had numerically more reactivations, while MMF maintenance had more infections.

Read Article
Dead Words Eulogy Cover Image

ICYMI: Dead Words Eulogy

Jack Cush, MD

The trouble with rheumatology may be the words we live by. Welcome to the eulogy for rheumatology 'dead words'. We're here today to celebrate the loss of rheumatology past. These are dead words in rheumatology, words fortified unfortunately by history and habit. The lexicon of rheumatology is unique, it's challenging and it's mostly incomprehensible to those who don't know...but those are the cornerstones of the greatest of medical subspecialties. 

Read Article
Malar,rash,SLE, Lupus

ICYMI: JAMA: SLE Review

Jack Cush, MD

Drs. Caroline Siegel and Lisa Sammaritano (from HSS in NYC) have published an impressive overview of systemic lupus erythematosus (SLE) in JAMA. This timely, well-written review covers the many complexities of this multi-organ disorder that affects nearly 3.4 million people worldwide.

Read Article
RheumNow Podcast square

Future Big BiTEs (6.28.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.

Read Article
pills-14550__180_0.jpg

Factors Affecting Hydroxychloroquine Adherence

Jack Cush, MD

A study from the University of British Columbia has evaluated the trajectories of hydroxychloroquine (HCQ) use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence. 

Read Article
kidney-147499_640.png

Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis

Jack Cush, MD

A multicenter cohort study of systemic lupus erythematosus patients with type 2 diabetes has shown the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors associated with a significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use.

Read Article
ICYMI: JAMA: SLE Review https://t.co/GJJSOYZru2 https://t.co/mCgWy27yPr

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @yuz6yusof #EULAR2024 OP0180 Can we safely taper GC in #lupus patients who are in remission? Single study in Italy showed in pts with SLEDAI=0 + pred =<5mg/d + stable IS/HCQ, GC discontinuation after proper tapering appeared safe and was associated with a low risk of flare

Dr. John Cush RheumNow ( View Tweet)

Factors Affecting Hydroxychloroquine Adherence A study from the University of British Columbia has evaluated the trajectories of HCQ use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence. https://t.co/kDUxVCfRGt https://t.co/1v79Vqdqo8

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 2,974 SLE pts taking hydroxychloroquine (HCQ) found 584 w/ ≥1 hospitalization for SLE. Taking Lower doses of HCQ (≤5 mg/kg/d) or <400 mg/d were assoc w/ increased hospitalizations for active SLE (adjusted OR 4.20 & aOR 3.39, respectively) https://t.co/QbLBMtBO30 https://t.co/b63bC0SKsf

Links:

Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria. https://t.co/7hJeTf3O6y https://t.co/V43YHjhEhn

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @yuz6yusof #EULAR2024 Cutaneous #lupus is variable &amp; can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) #EULARBEST

Dr. John Cush RheumNow ( View Tweet)

Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis https://t.co/QKXUxyhPUd https://t.co/Lx0VrBGqtg

Links:

Dr. John Cush RheumNow ( View Tweet)
RT @yuz6yusof #EULAR2024 OP0043 Data from UK BILAG-BR registry showed in n&gt;100 patients w neuropsychiatric #lupus (NPSLE), over 2/3 improved with rituximab. NPSLE tended to occur with other #SLE features and with high level of organ damage @RheumNow https://t.co/45OM0PLtjM

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 387 lupus nephritis pts found pulmonary HTN in 15%. An increased risk of PH was seen w/ eGFR <30, and w/ low Hgb, low triglycerides. PH was independently associated with a higher risk (HR ~ 2.0) of all-cause mortality and adverse renal outcomes https://t.co/hdLjOZc9TI https://t.co/60lhdo93lm

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 2,974 SLE pts taking hydroxychloroquine (HCQ) found 584 w/ ≥1 hospitalization for SLE. Taking Lower doses of HCQ (≤5 mg/kg/d) or <400 mg/d were assoc w/ increased hospitalizations for active SLE (adjusted OR 4.20 & aOR 3.39, respectively) https://t.co/xXLiGFoU3L https://t.co/Sy36aOG81Y

Links:

Dr. John Cush RheumNow ( View Tweet)
9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024

Dr. John Cush RheumNow ( View Tweet)

Tapering Treatment for Lupus Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus. https://t.co/ijy5OwIoCe https://t.co/7yQIxW70Zd

Links:

Dr. John Cush RheumNow ( View Tweet)
Cognitive Function in Older Adults: Worse in Lupus Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria. https://t.co/zedGdNbHw4 https://t.co/DIHvkEZRVk

Links:

Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria. https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×